CU20140028A7 - Compuesto de benzotiazolona - Google Patents

Compuesto de benzotiazolona

Info

Publication number
CU20140028A7
CU20140028A7 CU2014000028A CU20140028A CU20140028A7 CU 20140028 A7 CU20140028 A7 CU 20140028A7 CU 2014000028 A CU2014000028 A CU 2014000028A CU 20140028 A CU20140028 A CU 20140028A CU 20140028 A7 CU20140028 A7 CU 20140028A7
Authority
CU
Cuba
Prior art keywords
benzotiazolona
composite
compound
present
provides
Prior art date
Application number
CU2014000028A
Other languages
English (en)
Other versions
CU24303B1 (es
Inventor
Jun Cao
Bernhard Erb
Robin Alec Fairhurst
Arnaud Grandeury
Shinji Hatakeyama
Magadalena Koziczak-Holbro
Xinzhong Lai
Philipp Lustenberger
Bernd Riebesehl
Nicola Tufilli
Thomas Ullrich
Xiang Wu
Jianguang Zhou
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47010668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20140028(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CU20140028A7 publication Critical patent/CU20140028A7/es
Publication of CU24303B1 publication Critical patent/CU24303B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/08—Acetic acid
    • C07C53/10—Salts thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromonomer-Based Addition Polymer (AREA)

Abstract

La presente invención proporciona un compuesto de la fórmula( I) en forma libre o en forma de una sal farmacéuticamente aceptable, Un método para fabricar el compuesto de la invención, y sus usos terapéuticos. La presente invención proporciona además una combinación de agentes farmacológicamente activos y composiciones farmacéuticas.
CUP2014000028A 2011-09-06 2012-09-05 Compuesto de benzotiazolona CU24303B1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2011079379 2011-09-06
PCT/IB2012/054580 WO2013035047A1 (en) 2011-09-06 2012-09-05 Benzothiazolone compound

Publications (2)

Publication Number Publication Date
CU20140028A7 true CU20140028A7 (es) 2014-05-27
CU24303B1 CU24303B1 (es) 2018-01-10

Family

ID=47010668

Family Applications (1)

Application Number Title Priority Date Filing Date
CUP2014000028A CU24303B1 (es) 2011-09-06 2012-09-05 Compuesto de benzotiazolona

Country Status (38)

Country Link
US (6) US8933108B2 (es)
EP (1) EP2753609B1 (es)
JP (2) JP6130835B2 (es)
KR (2) KR101800140B1 (es)
CN (2) CN103781771B (es)
AP (1) AP3830A (es)
AR (1) AR087787A1 (es)
AU (1) AU2013200422C1 (es)
BR (1) BR112014004732A2 (es)
CA (1) CA2845766A1 (es)
CL (1) CL2014000493A1 (es)
CO (1) CO6900147A2 (es)
CR (1) CR20140114A (es)
CU (1) CU24303B1 (es)
CY (1) CY1118585T1 (es)
DK (1) DK2753609T3 (es)
EA (1) EA022909B1 (es)
ES (1) ES2615052T3 (es)
GT (1) GT201400042A (es)
HR (1) HRP20170075T1 (es)
HU (1) HUE030530T2 (es)
IL (1) IL231235A (es)
JO (1) JO3192B1 (es)
LT (1) LT2753609T (es)
MX (1) MX345405B (es)
MY (1) MY163301A (es)
PE (1) PE20141993A1 (es)
PL (1) PL2753609T3 (es)
PT (1) PT2753609T (es)
RS (1) RS55468B1 (es)
SG (1) SG2014013114A (es)
SI (1) SI2753609T1 (es)
TN (1) TN2014000060A1 (es)
TW (1) TWI555738B (es)
UA (1) UA114295C2 (es)
UY (1) UY34312A (es)
WO (1) WO2013035047A1 (es)
ZA (2) ZA201401112B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA117092C2 (uk) 2011-09-06 2018-06-25 Байєр Інтеллектуал Проперті Гмбх Амінозаміщені імідазопіридазини
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
HUE033655T2 (en) * 2012-08-30 2017-12-28 Novartis Ag Benzothiazolone Compounds with Beta-2-Adrenoceptor Effects
CN104797585B (zh) 2012-11-19 2017-08-15 拜耳医药股份公司 氨基咪唑并哒嗪
PL2961391T3 (pl) * 2013-02-28 2017-10-31 Novartis Ag Preparat zawierający pochodną benzotiazolonu
US10967119B1 (en) 2019-04-01 2021-04-06 Azizi Bilal Wearable medication injecting device

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3855801T2 (de) * 1987-09-15 1997-07-03 Rowett Research Inst Anwendungsgebiete von beta-adrenergenen Agonisten
US20070082918A1 (en) * 1993-11-02 2007-04-12 Naftchi N E Neurologically active compounds and compounds with multiple activities
GB9405019D0 (en) 1994-03-15 1994-04-27 Smithkline Beecham Plc Novel compounds
ZA967892B (en) 1995-09-21 1998-03-18 Lilly Co Eli Selective β3 adrenergic agonists.
WO1999009018A1 (fr) 1997-08-14 1999-02-25 Kirin Beer Kabushiki Kaisha DERIVES DE BENZOTHIAZOLONE PRESENTANT UNE ACTIVITE SELECTIVE D'AGONISTE DU RECEPTEUR β2
AU760250B2 (en) 1998-12-04 2003-05-08 Neurosearch A/S New benzimidazolone-, benzoxazolone-, or benzothiazolone derivatives as ion channel modulating agents
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
US6872723B2 (en) * 2002-01-28 2005-03-29 Wyeth Stabilized difloxacin injectable solution
US6743797B2 (en) * 2002-02-22 2004-06-01 Chantest, Inc. Methods for treating cardiac arrhythmia
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
AR040962A1 (es) * 2002-08-09 2005-04-27 Novartis Ag Compuestos derivados de tiazol 1,3-2-ona, composicion farmaceutica y proceso de preparacion del compuesto
GB0225540D0 (en) 2002-11-01 2002-12-11 Glaxo Group Ltd Medicinal compounds
CA2514733A1 (en) 2003-02-28 2004-09-16 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
BRPI0408680A (pt) * 2003-03-26 2006-03-28 Pharmacia & Upjohn Co Llc processo para produzir álcoois e aminas enantiomericamente enriquecidos
JP4516064B2 (ja) * 2003-04-04 2010-08-04 ノバルティス アーゲー 気道疾患の処置のためのキノリン−２−オン誘導体
BRPI0411275A (pt) 2003-06-10 2006-08-01 Kalypsys Inc compostos de carbonila como inibidores de histona deacetilase para tratamento de doenças; composição farmacêutica; método de modular a atividade catalìtica de hdac; método de tratar doença em um indivìduo; utilização de um composto ou composição; método de inibir hdac
JP2007503472A (ja) * 2003-06-10 2007-02-22 カリプシス・インコーポレーテッド 病気治療用のヒストン脱アセチル化酵素阻害剤としてのカルボニル化合物
WO2005004846A1 (en) 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations
WO2005004852A1 (en) 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations
CA2543858C (en) 2003-11-21 2014-04-15 Theravance, Inc. Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
GB0328490D0 (en) 2003-12-09 2004-01-14 Glaxo Group Ltd Medicinal compounds
JP2005187357A (ja) 2003-12-25 2005-07-14 Nippon Suisan Kaisha Ltd 選択的なβ２受容体アゴニスト活性を有するベンゾチアゾロン誘導体の製造方法
GB0402797D0 (en) 2004-02-09 2004-03-10 Novartis Ag Organic compounds
EP1595873A1 (de) 2004-05-13 2005-11-16 Boehringer Ingelheim Pharma GmbH & Co.KG Substituierte Cycloalkylderivate zur Behandlung von Atemswegerkrankungen
WO2005110990A1 (de) 2004-05-13 2005-11-24 Boehringer Ingelheim International Gmbh Hydroxy-substituierte benzkondensierte heterozyklen als betaagonisten zur behandlung von atemwegserkrankungen
JP2008507532A (ja) 2004-07-21 2008-03-13 セラヴァンス， インコーポレーテッド ジアリールエーテルβ２アドレナリン作用性レセプターアゴニスト
DE102004045648A1 (de) 2004-09-21 2006-03-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Betamimetika zur Behandlung von Atemwegserkrankungen
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
DE102005007654A1 (de) 2005-02-19 2006-08-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
TW200740781A (en) 2005-08-29 2007-11-01 Astrazeneca Ab Novel compounds
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
WO2007086078A2 (en) 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
KR101426093B1 (ko) 2006-02-10 2014-08-01 서미트 코포레이션 피엘씨 뒤시엔느 근이영양증의 치료
TW200745084A (en) 2006-03-08 2007-12-16 Astrazeneca Ab Novel compounds
GB0613154D0 (en) 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
CA2660707C (en) * 2006-08-10 2014-07-08 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure
TW200833670A (en) * 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
CN101678107A (zh) 2007-08-03 2010-03-24 萨米特公开有限公司 用于治疗杜兴型肌营养不良的药物组合物
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
GB0814728D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
GB0823140D0 (en) 2008-12-18 2009-01-28 Astrazeneca Ab New combination
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
GB201107985D0 (en) 2011-05-13 2011-06-29 Astrazeneca Ab Process
JO3192B1 (ar) 2011-09-06 2018-03-08 Novartis Ag مركب بنزوثيازولون
HUE033655T2 (en) * 2012-08-30 2017-12-28 Novartis Ag Benzothiazolone Compounds with Beta-2-Adrenoceptor Effects
PL2961391T3 (pl) 2013-02-28 2017-10-31 Novartis Ag Preparat zawierający pochodną benzotiazolonu

Also Published As

Publication number Publication date
AP2014007462A0 (en) 2014-02-28
MY163301A (en) 2017-09-15
AU2013200422B2 (en) 2014-08-07
KR20160038079A (ko) 2016-04-06
RS55468B1 (sr) 2017-04-28
SG2014013114A (en) 2014-07-30
JP6130835B2 (ja) 2017-05-17
US20150094346A1 (en) 2015-04-02
TW201317221A (zh) 2013-05-01
UY34312A (es) 2013-04-30
KR101628585B1 (ko) 2016-06-08
TN2014000060A1 (en) 2015-07-01
CR20140114A (es) 2014-05-06
US9913828B2 (en) 2018-03-13
WO2013035047A1 (en) 2013-03-14
AU2013200422C1 (en) 2015-01-15
ES2615052T3 (es) 2017-06-05
CN106187942B (zh) 2020-06-26
UA114295C2 (uk) 2017-05-25
PT2753609T (pt) 2017-02-08
CN103781771A (zh) 2014-05-07
PE20141993A1 (es) 2014-12-17
CO6900147A2 (es) 2014-03-20
US20130245080A1 (en) 2013-09-19
JP2014525472A (ja) 2014-09-29
JO3192B1 (ar) 2018-03-08
CN103781771B (zh) 2016-08-24
HRP20170075T1 (hr) 2017-03-24
AP3830A (en) 2016-09-30
CL2014000493A1 (es) 2014-10-03
DK2753609T3 (en) 2017-02-06
LT2753609T (lt) 2017-01-10
TWI555738B (zh) 2016-11-01
US20160075670A1 (en) 2016-03-17
CN106187942A (zh) 2016-12-07
IL231235A (en) 2017-09-28
JP2017132781A (ja) 2017-08-03
JP6340103B2 (ja) 2018-06-06
AU2013200422A1 (en) 2013-03-21
ZA201401112B (en) 2016-01-27
US20180140582A1 (en) 2018-05-24
GT201400042A (es) 2015-02-19
MX2014002688A (es) 2014-04-14
EP2753609B1 (en) 2016-11-09
EP2753609A1 (en) 2014-07-16
SI2753609T1 (sl) 2017-03-31
EA201490573A1 (ru) 2014-06-30
AR087787A1 (es) 2014-04-16
CY1118585T1 (el) 2017-07-12
KR101800140B1 (ko) 2017-11-21
US20150336914A1 (en) 2015-11-26
US20160279107A1 (en) 2016-09-29
US10251868B2 (en) 2019-04-09
EA022909B1 (ru) 2016-03-31
IL231235A0 (en) 2014-04-30
NZ621089A (en) 2015-07-31
KR20140057382A (ko) 2014-05-12
CU24303B1 (es) 2018-01-10
HUE030530T2 (en) 2017-05-29
US8933108B2 (en) 2015-01-13
CA2845766A1 (en) 2013-03-14
MX345405B (es) 2017-01-30
PL2753609T3 (pl) 2017-05-31
ZA201500790B (en) 2017-04-26
BR112014004732A2 (pt) 2017-03-28

Similar Documents

Publication Publication Date Title
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CR20140032A (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como modulares de receptores de c5a
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
MX2015016344A (es) Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades.
IN2015DN00185A (es)
MY163083A (en) Solid forms of a pharmaceutically active substance
GT201400012A (es) Compuesto inhibidor de la señalizacion de la trayectoria notch
ECSP11011526A (es) Aril-piridinas como inhibidoras de sintasa de aldosterona
CO6781541A2 (es) Derivados glucósidos y usos de los mismos
EA201390804A1 (ru) Лекарственная форма лакозамида для приема один раз в сутки
CR20140508A (es) Moduladores de la ruta del complemento y usos de los mismos
GT201400042A (es) Compuesto de benzotiazolona
UY35209A (es) Compuestos tricíclicos
UY35211A (es) Compuestos tricíclicos
CR20190144A (es) Compuestos de aza-indazol para usar en lesiones de tendones y/o ligamentos
UY33348A (es) Compuestos de furopiridina y usos de los mismos
EA201690327A1 (ru) Терапевтические способы
EP2785379A4 (en) PEPTIDE-MEDIATED ADMINISTRATION OF ACTIVE AGENTS ACROSS THE HEMATO-ENCEPHALIC BARRIER
AR084169A1 (es) Combinacion que comprende un derivado de la familia de las combretastatinas y cetuximab
TN2015000058A1 (en) Salts of benzothiazolone compound as beta-2-adrenoceptor agonist
UY33857A (es) Compuestos de tiofeno 2,3,5-trisustituidos y usos de los mismos.
CU20140007A7 (es) Compuestos de tetrahidropirido-piridina y tetrahidropirido- pirimidina y su uso como moduladores de receptores de c5a
CL2010001230A1 (es) Metodo para inhibir la melanogenesis que comprende administrar un compuesto esteroidal; composicin farmaceutica; formulacion topica, util en el tratamiento de una enfermedad o condicion que involucra melanogenesis.